All
Xtandi Improves Progression-Free Survival Over Casodex in Metastatic Prostate Cancer
January 28th 2015Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.
Jenna Forsythe Gives Advice to Patients Newly Diagnosed with Cancer
January 27th 2015Jenna Forsythe, an oncology nurse at John Theurer Cancer Center in Hackensack, New Jersey, says many patients newly diagnosed with cancer will need to allow themselves to lean on their medical team, especially in regards to symptom management.
Rapid Approval Expected for First PD-1 Inhibitor in Lung Cancer
January 27th 2015Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non-small cell lung cancer (NSCLC), following their initial debut in 2012. What's next?
New Studies Show Importance of Diet for Lowering Breast Cancer Risk and Preventing Recurrence
January 23rd 2015Two recent studies outline the importance of nutrition in preventing obesity-related cancers, as well as the potential benefits of a nutrition education intervention in preventing breast cancer recurrence.
An Advocate's View of ASCO GI Symposium 2015
January 21st 2015Last week, I walked the massive halls of Moscone West in San Francisco and attended the Gastrointestinal Cancers Symposium, better known as ASCO GI. It is a meeting I always feel quite privileged to attend; it offers a glimpse into the work, passion, and expertise that goes into the many aspects of being able to live with metastatic colon cancer.
Adjusted Regimen of Abraxane and Gemzar Less Toxic in Pancreatic Cancer
January 20th 2015Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
January 20th 2015Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Updated Study Results Shows Activity for Keytruda in Gastric Cancer
January 16th 2015Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.
Integrating PD-1 Inhibitors into the Treatment of Melanoma
January 14th 2015In the past four months, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved for the treatment of advanced melanoma. Jeffery S. Weber, a senior member at Moffitt Cancer Center in Tampa, Fla., provides insight on what this means for treating patients.
Several Cancer Therapies Up for FDA Review in 2015
January 13th 2015The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Higher Vitamin D Levels Associated with Higher Survival in Metastatic Colorectal Cancer
January 13th 2015Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of eight months longer and experienced greater disease-free survival after their cancer treatment, according to research reported at the 2015 Gastrointestinal Cancers Symposium.